Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 2 Study of HKI-272 in Subjects With Advanced Breast Cancer.

Trial Profile

Phase 2 Study of HKI-272 in Subjects With Advanced Breast Cancer.

Phase of Trial: Phase II

Latest Information Update: 28 Sep 2018

At a glance

  • Drugs Neratinib (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Puma Biotechnology
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 26 Jun 2018 Status changed from active, no longer recruiting to completed.
    • 09 Dec 2017 Results (n=966) of pooled subgroup analysis of NCT00445458, NCT00706030, NCT00398567, NCT00915018, NCT00741260 and NCT00300781trials assessing safety and efficacy of neratinib therapy in Asian patients from China, Hong Kong, Japan, Korea, Malaysia, Singapore, and Taiwan presented at the 40th Annual San Antonio Breast Cancer Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top